Medicine & Life Sciences
Breast Neoplasms
100%
Drug Therapy
42%
Neoplasms
37%
Kaposi's Sarcoma
31%
Neoadjuvant Therapy
28%
Acquired Immunodeficiency Syndrome
27%
Therapeutics
25%
Trastuzumab
25%
liposomal doxorubicin
21%
Docetaxel
21%
AIDS-related Kaposi sarcoma
20%
HIV
18%
Bevacizumab
17%
Survival
17%
Anastrozole
16%
Triple Negative Breast Neoplasms
16%
Paclitaxel
16%
Carboplatin
14%
Irinotecan
14%
Doxorubicin
13%
Safety
13%
Recurrence
12%
Progression-Free Survival
12%
Anthracyclines
12%
Biomarkers
12%
Maximum Tolerated Dose
12%
gemcitabine
11%
Breast
11%
palbociclib
10%
Estrogen Receptors
10%
Radiotherapy
10%
Non-Small Cell Lung Carcinoma
10%
Pharmacokinetics
10%
taxane
9%
Residual Neoplasm
9%
Randomized Controlled Trials
9%
Lapatinib
9%
Lymphoma
9%
anti-IGF-1R antibody A12
8%
Capecitabine
8%
Heterografts
8%
Non-Hodgkin's Lymphoma
8%
Bortezomib
8%
Placebos
8%
Adjuvant Chemotherapy
8%
veliparib
7%
Estrogens
7%
Confidence Intervals
7%
Toll-Like Receptor 8
7%